Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Blood blood.2024025868.

https://doi.org/10.1182/blood.2024025868

Published: 2024

Includes: Supplemental data

Journal Articles

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Rebecca Svanberg Teglgaard, Rudi Agius, Caspar da Cunha-Bang, Tereza Faitova, Christian Brieghel, Hans Jakob Hartling, Hanne Vibeke Marquart, Robert Schou Pedersen, Christian Bjørn Poulsen, Mark-David Levin, Fransien De Boer, Koen de Heer, Rikke Kragh Lauridsen, Joanne Reekie, Anders Österborg, Jeanette Lundin, Magdalena Kättström, Sisse Rye Ostrowski, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 4609.

https://doi.org/10.1182/blood-2024-204985

Published: 2024

Journal Articles

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1013.

https://doi.org/10.1182/blood-2024-207452

Published: 2024

Journal Articles

Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2024-206636

Published: 2024

Journal Articles

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Blood (2024) 144 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2024-205968

Published: 2024

Journal Articles

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

Blood (2024) 144 (Supplement 1): 4739.

https://doi.org/10.1182/blood-2024-208754

Published: 2024

Journal Articles

No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

A. Vera de Jonge, Carolien Duetz, Wassilis S.C Bruins, Charlotte L.B.M. Korst, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Marcel Nijland, Marjolein Van Der Poel, Koen de Heer, Clara Klerk, Leonie Strobbe, Margriet Oosterveld, Rinske Boersma, Harry R. Koene, Erik van Werkhoven, Martine E.D. Chamuleau, Tuna Mutis

Blood (2023) 142 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2023-180734

Published: 2023

Journal Articles

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Blood (2023) 142 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2023-181707

Published: 2023

Journal Articles

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Blood (2023) 142 (Supplement 1): 342.

https://doi.org/10.1182/blood-2023-180006

Published: 2023

Journal Articles

Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3529–3531.

https://doi.org/10.1182/blood-2022-168668

Published: 2022

Journal Articles

Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients with Chronic Lymphocytic Leukaemia

Sabine Haggenburg, Hannah Garcia Garrido, Iris Kant, Fransien De Boer, Sabina Kersting, Doreen te Raa, Djamila E. Issa, Henny G. Otten, Hein P.J. Visser, Arnon P. Kater, Abraham Goorhuis, Koen de Heer

Blood (2022) 140 (Supplement 1): 7020–7022.

https://doi.org/10.1182/blood-2022-166046

Published: 2022

Journal Articles

Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Blood (2022) 140 (Supplement 1): 4137–4139.

https://doi.org/10.1182/blood-2022-163209

Published: 2022

Journal Articles

First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study

Mirian Brink, Arie C. van der Spek, Koen de Heer, Sabina Kersting, Lidwine W. Tick, Hanneke M. van der Straaten, Rogier Mous, Mark-David Levin, Doreen te Raa, Michel van Gelder, Jeanette K. Doorduijn, Arnon P. Kater, Gerwin Huls, Mar Bellido

Blood (2022) 140 (Supplement 1): 3788–3789.

https://doi.org/10.1182/blood-2022-168849

Published: 2022

Journal Articles

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

A.Vera de Jonge, Carolien Duetz, Wassilis S.C. Bruins, Erik D. van Werkhoven, Marcel Nijland, Marjolein W.M. Van Der Poel, Koen de Heer, Clara P.W. Klerk, Yorick Sandberg, Rob Fijnheer, Pim Mutseaers, Djamila E. Issa, Lara H. Böhmer, Roel J.W. Van Kampen, Otto J. Visser, Daphne de Jong, Josée M. Zijlstra, Tuna Mutis, Martine E.D. Chamuleau

Blood (2022) 140 (Supplement 1): 9298–9299.

https://doi.org/10.1182/blood-2022-163068

Published: 2022

Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Blood (2021) 138 (Supplement 1): 80.

https://doi.org/10.1182/blood-2021-152112

Published: 2021

Journal Articles

High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

A. Vera de Jonge, Erik D. van Werkhoven, Marcel Nijland, Koen de Heer, Marjolein W.M. Van Der Poel, Yorick Sandberg, Clara Klerk, Esther E.E. Drees, Margaretha GM Roemer, Daphne de Jong, D. Michiel Pegtel, Bronno van der Holt, Tuna Mutis, Josée M Zijlstra, Marie José Kersten, Martine E.D Chamuleau

Blood (2021) 138 (Supplement 1): 1414.

https://doi.org/10.1182/blood-2021-146812

Published: 2021

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Blood (2019) 134 (Supplement_1): 695.

https://doi.org/10.1182/blood-2019-121694

Published: 2019

NARROW

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients with Chronic Lymphocytic Leukaemia

Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only